Abstract: The present disclosure relates to novel PD 1 agonist antibodies and methods and uses of anti human PD 1 agonist antibodies for the treatment of autoinflammatory and/or autoimmune diseases. Also provided are doses and dosing regimens for the methods and uses of anti human PD 1 agonist antibodies for the treatment of autoinflammatory and/or autoimmune diseases such as RA.